Novo Nordisk Reaches Agreement With U.S. Administration To Expand Access To GLP-1 Medicines At Lower Cost For Americans

Novo Nordisk has announced an agreement with the U.S. Administration to lower drug prices starting in 2026 and improve patient access and affordability for its semaglutide-based medicines, including Wegovy® and Ozempic®. The initiative will cover patients in U.S. Medicare Part D, Medicaid, and direct-to-patient cash channels. As part of the agreement, Medicare Part D coverage for anti-obesity medications will be introduced through a pilot program designed to include a majority of Part D beneficiaries. Additionally, Novo Nordisk is expected to receive a three-year tariff exemption, further supporting the implementation of this initiative.

Mike Doustdar, President and CEO of Novo Nordisk, emphasized that the company has long been committed to ensuring affordable access to its innovative treatments. He stated that this agreement will make semaglutide medicines available to more patients in the United States at a reduced cost. Doustdar also noted that expanding Medicare coverage to include obesity medications is an important step toward improving access for people living with obesity, allowing them to receive authentic Wegovy®.

Novo Nordisk expects a direct, low single-digit negative impact on its global sales growth in 2026 as a result of the pricing adjustments. The implementation of the agreement is set to begin in 2026. The company also clarified that the forward-looking statements included on page 28 of its financial report for the first nine months of 2025 (Company Announcement No. 31/2025) apply to this announcement as well. Novo Nordisk plans to provide its financial outlook for 2026 alongside the release of its full-year 2025 results on February 4, 2026. Following this announcement, Novo Nordisk and the U.S. Administration will work together to finalize the specific details of the agreement.